A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (Azalea)

Principal Investigator

Prof Lawrence W M Impey

Contact us

Email: osprea@wrh.ox.ac.uk

IRAS number

1008016